GlaxoSmithKline: Uterine Cervical Neoplasms trials

The registry lists 33 Uterine Cervical Neoplasms studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 28 have results posted.

Phase 1 3Phase 2 4Phase 3 19Phase 4 4No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With PembrolizumabCompletedNCT03674567Phase 1/2Results posted
• Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 StudyCompletedNCT03629886Phase 4Results posted
• Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old GirlsCompletedNCT01381575Phase 3Results posted
• Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study SubjectsCompletedNCT01190176Phase 3Results posted
• Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected FemalesCompletedNCT01031069Phase 4Results posted
• Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female SubjectsCompletedNCT00947115Phase 3Results posted
• Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study SubjectsCompletedNCT00937950Phase 3Results posted
• Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.CompletedNCT00877877Phase 3Results posted
• Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or ThailandCompletedNCT00849381Phase 3Results posted
• Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the USCompletedNCT00799825Phase 3Results posted
• Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female SubjectsCompletedNCT00779766Phase 3Results posted
• A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.TerminatedNCT00730847Phase 4Results posted
• Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female SubjectsCompletedNCT00652938Phase 3Results posted
• Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)CompletedNCT00637195Phase 3Results posted
• Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected FemalesCompletedNCT00586339Phase 2Results posted
• Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female SubjectsCompletedNCT00578227Phase 3Results posted
• Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of AgeCompletedNCT00552279Phase 3Results posted
• A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese FemalesCompletedNCT00549900Phase 1Results posted
• Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North AmericaCompletedNCT00546078Phase 2Results posted
• Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 YrsCompletedNCT00541970Phase 1Results posted
• Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy AdolescentsCompletedNCT00534638Phase 4Results posted
• Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of AgeCompletedNCT00492544Phase 3Results posted
• A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 YearsCompletedNCT00485732Phase 3Results posted
• Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical CancerCompletedNCT00430781Phase 2Results posted
• Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of AgeCompletedNCT00423046Phase 3Results posted
• Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 YearsCompletedNCT00345878Phase 3Results posted
• Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and OlderCompletedNCT00294047Phase 3Results posted
• Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy ParticipantsCompletedNCT00128661Phase 3Results posted
• Human Papillomavirus (HPV) Type Distribution in Adult Women Diagnosed With Invasive Cervical Cancer in New ZealandCompletedNCT01328028
• Cross-sectional Study on Human Papillomavirus Type Distribution in Adult Women Diagnosed With Cervical CancerCompletedNCT01221987
• Study on the Prevalence of Human Papillomavirus Types in Women >= 15 Years of Age in the Kingdom of Saudi ArabiaCompletedNCT01213459
• Type Distribution of Human Papillomavirus in Adult African Women Diagnosed With Invasive Cervical CancerCompletedNCT01207999
• A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 YearsCompletedNCT00306241Phase 3